Neither Outcomes4Me nor any participants in or contributors to any webinar, article or content endorses or recommends any products or services. Consult your physician regarding any treatment or therapy.
Tune into a patient-focused Q&A with MD Anderson’s Dr. Scott Kopetz, a leading expert in colorectal cancer. We break down staging, biomarkers, treatment paths, and trials. We also cover what’s new in CRC from KRAS-targeted combinations to ctDNA blood tests that help personalize care, plus evolving organ-preservation approaches in rectal cancer.
Dr. Scott Kopetz, MD, PhD, FACP is a colorectal cancer physician–scientist at The University of Texas MD Anderson Cancer Center, where he serves as Professor and Deputy Chair for Translational Research in the Department of GI Medical Oncology. He leads MD Anderson’s GI Program within the Cancer Center Support Grant and helps integrate lab discoveries into patient care. Dr. Kopetz’s research has advanced precision therapy in CRC, including KRAS-targeted strategies such as adagrasib plus cetuximab for KRAS G12C–mutated disease.
